• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epilepsy Behav . Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwi

tetano

Editor, Senior Moderator
Epilepsy Behav


. 2023 Jan 3;139:109070.
doi: 10.1016/j.yebeh.2022.109070. Online ahead of print.
Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwide survey


Megumi Nonaka[SUP] 1 [/SUP], Shuichiro Neshige[SUP] 2 [/SUP], Hidetada Yamada[SUP] 1 [/SUP], Haruka Ishibashi[SUP] 1 [/SUP], Yoshiko Takebayashi[SUP] 1 [/SUP], Masahiro Nakamori[SUP] 1 [/SUP], Shiro Aoki[SUP] 1 [/SUP], Yu Yamazaki[SUP] 1 [/SUP], Takeo Shishido[SUP] 3 [/SUP], Dai Agari[SUP] 4 [/SUP], Kazuhide Ochi[SUP] 5 [/SUP], Koji Iida[SUP] 6 [/SUP], Hirofumi Maruyama[SUP] 7 [/SUP]



Affiliations

Abstract

Objective: This study aimed to identify seizure outcomes in people with epilepsy (PWE) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) messenger RNA vaccination.
Methods: We examined PWE (n = 332, age ≥ 14 years) treated in four tertiary hospitals between 2021 and 2022 to assess the incidence of seizure worsening following vaccination using closed questions. We identified the clinical factors associated with worsening and 6-month vaccination outcomes. We also conducted a nationwide survey on self-reported seizure worsening using open questions, to which 261 general practitioners from 99 institutes contributed.
Results: Of the 282 PWE vaccinated in the four hospitals, 16 (5.7%) exhibited seizure worsening; most of them emerged within 48 h of vaccination and were not sustained. Thus, all PWE were at baseline condition 6 months after their vaccination. PWE with seizure worsening were more significantly associated with focal impaired awareness seizures (p < 0.001), high seizure frequency (p = 0.025), and drug-resistant epilepsy (p = 0.007) at baseline compared to PWE without worsening. Multivariate logistic regression analysis revealed that focal impaired awareness seizures were independently associated with worsening (odds ratio, 7.0; 95% confidence interval, 1.50-32.77). A nationwide survey of 5156 PWE data (real-world data) confirmed an extremely low incidence rate of self-reported seizure worsening (0.43%).
Significance: Some PWE, particularly refractory focal epilepsy, exhibit seizure worsening. However, the worsening events were infrequent, non-sustainable, and probably under-reported by PWE, suggesting that there is little evidence that worsening seizures discourage current and future vaccinations.

Keywords: Epidemic; Focal impaired awareness seizure; SARS-CoV2 mRNA vaccination; Seizure worsening; Temporal lobe epilepsy.
 
Back
Top Bottom